Maravai LifeSciences(MRVI) - 2023 Q3 - Earnings Call Presentation

Q3 2023 Financial Performance - Revenue reached $67 million[7] - Adjusted EPS was negative, at ($0.01) per share[7] - Adjusted EBITDA stood at $12 million[16] - Base Nucleic Acid Production (NAP) revenue totaled $36 million[7] - NAP revenue reached $51 million[16] - Biologics Safety Testing (BST) revenue was $16 million[33] Updated 2023 Financial Guidance - Revenue guidance was updated to $275 to $285 million[51] - CleanCap® COVID-19 revenue is projected at $61 million[51] - Adjusted EPS guidance was updated to ($0.01) to $0.01 per share[51] - Adjusted EBITDA guidance was updated to $55 to $60 million[51] Cost Savings and Restructuring - The company is targeting at least $30 million in annualized cost savings through workforce and expense reductions[19,35] - A workforce reduction of approximately 15% is planned, targeting $23 million in savings[19] - Non-labor expense reductions are expected to yield $7 million in savings[19]